Cardiovascular disease after treatment for Hodgkin's lymphoma: An analysis of nine collaborative EORTC-LYSA trials

The Lancet Haematology

Volumn 2, Issue 11, 2015, Pages e492-e502

  Maraldo, Maja V ^a   Giusti, Francesco ^b   Vogelius, Ivan R ^a   Lundemann, Michael ^a,c   Van der Kaaij, Marleen A E ^d   Ramadan, Safaa ^e   Meulemans, Bart ^b   Henry Amar, Michel ^f   Aleman, Berthe M P ^g   Raemaekers, John ^h   Meijnders, Paul ⁱ   Moser, Elisabeth C ^j   Kluin Nelemans, Hanneke C ^k   Feugier, Pierre ^l   Casasnovas, Olivier ^m   Fortpied, Catherine ^b   Specht, Lena ^a  

^a Rigshospitalet   (Denmark)

^b European Organisation of Research and Treatment of Cancer   (Belgium)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CAIRO UNIVERSITY   (Egypt)

^f CENTRE FRANÇOIS BACLESSE   (France)

^g NETHERLANDS CANCER INSTITUTE   (Netherlands)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ UNIVERSITY OF ANTWERP   (Belgium)

^j Champalimaud Cancer Centre   (Portugal)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l CHU NANCY BRABOIS   (France)

^m DIJON UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; EPIRUBICIN; VINBLASTINE; VINCRISTINE; VINCA ALKALOID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CEREBROVASCULAR ACCIDENT; CHILD; CONGESTIVE HEART FAILURE; FEMALE; HEART ARRHYTHMIA; HODGKIN DISEASE; HUMAN; ISCHEMIC HEART DISEASE; LIFE SITUATION QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERICARDITIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; QUESTIONNAIRE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); VALVULAR HEART DISEASE; VEIN THROMBOSIS; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; COMPLICATION; RADIOTHERAPY; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVOR; YOUNG ADULT;

ADULT; AGED; ANTHRACYCLINES; CARDIOVASCULAR DISEASES; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; RADIATION DOSAGE; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS; VINCA ALKALOIDS; YOUNG ADULT;

EID: 84955214707     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00153-2     Document Type: Article

References (32)

1. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007; 109: 1878-86.
2. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 1993; 270: 1949-55.
3. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290: 2831-37.
4. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99: 206-14.
5. van Nimwegen FA, Schaapveld M, Janus CP, et al. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med 2015; 175: 1007-17.
6. Matasar MJ, Ford JS, Riedel ER, et al. Late morbidity and mortality in patients with Hodgkin's lymphoma treated during adulthood. J Natl Cancer Inst 2015; 107: djv018.
7. Specht L, Yahalom J, Illidge T, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 2014; 89: 854-62.
8. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 2003; 348: 2396-406.
9. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199-206.
10. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-52.
11. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-99.
12. Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for Hodgkin lymphoma. J Natl Cancer Inst 2015; 107: djv008.
13. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009; 339: b4606.
14. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011; 154: 23-31.
15. Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988; 6: 239-52.
16. Carde P, Hagenbeek A, Hayat M, et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1993; 11: 2258-72.
17. Eghbali H, Brice P, Creemers GJ, et al. Comparison of three radiation dose levels after EBVP regimen in favorable supradiaphragmatic clinical stages (CS) I-II Hodgkin's Lymphoma (HL): preliminary results of the EORTC-GELA H9-F trial. Blood 2005; 106 (suppl): 814 (abstr).
18. Ferme C, Divine M, Vranovsky A, et al. Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial. Blood 2005; 106 (suppl): 813 (abstr).
19. Noordijk EM, Carde P, Dupouy NL, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 3128-35.
20. Somers R, Carde P, Henry-Amar M, et al. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 1994; 12: 279-87.
21. Tubiana M, Henry-Amar M, Hayat M, Breur K, Werf-Messing B, Burgers M. Long-term results of the E.O.R.T.C. randomized study of irradiation and vinblastine in clinical stages I and II of Hodgkin's disease. Eur J Cancer 1979; 15: 645-57.
22. Tubiana M, Hayat M, Henry-Amar M, Breur K, Werf Messing B, Burgers M. Five-year results of the EORTC randomized study of splenectomy and spleen irradiation in clinical stages I and II of Hodgkin's disease. Eur J Cancer 1981; 17: 355-63.
23. Cox DR. Regression models and life tables. J R Stat Soc Series B Methodol 1972; 34: 187-220.
24. Maraldo MV, Lundemann M, Vogelius IR, Specht L. A new method to estimate doses to the normal tissues after past extended and involved field radiotherapy for Hodgkin lymphoma. Radiother Oncol 2015; 114: 206-11.
25. Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dosevolume effects in the heart. Int J Radiat Oncol Biol Phys 2010; 76 (suppl 3): S77-85
26. Deasy JO, Blanco AI, Clark VH. CERR: a computational environment for radiotherapy research. Med Phys 2003; 30: 979-85.
27. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993; 80: 557-72.
28. Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117: 412-18.
29. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008; 49: 1486-93.
30. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013; 368: 987-98.
31. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004; 57: 1096-103.
32. Walker MK, Whincup PH, Shaper AG, Lennon LT, Thomson AG. Validation of patient recall of doctor-diagnosed heart attack and stroke: a postal questionnaire and record review comparison. Am J Epidemiol 1998; 148: 355-61.